Terms: = Endocrine gland cancer AND MSN, P26038, 4478, ENSG00000147065 AND Treatment
15 results:
1. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
[TBL] [Abstract] [Full Text] [Related]
2. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the treatment of Pancreatic cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract] [Full Text] [Related]
4. Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/SLC4A4 axis.
Wang Y; Zhang M; Zhang L; Zhou M; Wang E
Clin Exp Metastasis; 2023 Feb; 40(1):53-67. PubMed ID: 36479657
[TBL] [Abstract] [Full Text] [Related]
5. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract] [Full Text] [Related]
6. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract] [Full Text] [Related]
7. A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into Pancreatic Tumor to Overcome Matrix and Reflux Barriers.
Huo T; Zhang X; Qian M; Nie H; Liang D; Lin C; Yang Y; Guo W; Lächelt U; Huang R
Adv Sci (Weinh); 2022 Jul; 9(20):e2200608. PubMed ID: 35508899
[TBL] [Abstract] [Full Text] [Related]
8. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract] [Full Text] [Related]
9. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
Wang P; Magdolen V; Seidl C; Dorn J; Drecoll E; Kotzsch M; Yang F; Schmitt M; Schilling O; Rockstroh A; Clements JA; Loessner D
Br J Cancer; 2018 Oct; 119(7):1-9. PubMed ID: 30287916
[TBL] [Abstract] [Full Text] [Related]
10. Cellular Migration Ability Is Modulated by Extracellular Purines in Ovarian Carcinoma SKOV-3 Cells.
Martínez-Ramírez AS; Díaz-Muñoz M; Battastini AM; Campos-Contreras A; Olvera A; Bergamin L; Glaser T; Jacintho Moritz CE; Ulrich H; Vázquez-Cuevas FG
J Cell Biochem; 2017 Dec; 118(12):4468-4478. PubMed ID: 28464260
[TBL] [Abstract] [Full Text] [Related]
11. A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
Ligia Cebotaru C; Zenovia Antone N; Diana Olteanu E; Bejinariu N; Buiga R; Todor N; Ioana Iancu D; Eliade Ciuleanu T; Nagy V
J BUON; 2016; 21(3):698-708. PubMed ID: 27569093
[TBL] [Abstract] [Full Text] [Related]
12. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract] [Full Text] [Related]
13. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.
Chen Y; Wang X; Liu T; Zhang DS; Wang Y; Gu H; Di W
Int J Nanomedicine; 2015; 10():2579-94. PubMed ID: 25848273
[TBL] [Abstract] [Full Text] [Related]
14. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract] [Full Text] [Related]
15. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract] [Full Text] [Related]
